Japan· JP-4291483A1028
レチファンリマブ（遺伝子組換え）
A medicinal product containing レチファンリマブ（遺伝子組換え）, registered in Japan by インサイト・バイオサイエンシズ・ジャパン, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- レチファンリマブ（遺伝子組換え）
- Manufacturer
- インサイト・バイオサイエンシズ・ジャパン
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
レチファンリマブ（遺伝子組換え） in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesZYNYZIncyte Corporation
- SwitzerlandZYNYZ 500 mg/20 ml, solution à diluer pour perfusionIncyte Biosciences International Sàrl
- CzechiaZYNYZIncyte Biosciences Distribution B.V., Amsterdam
- SpainZYNYZ 500 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONIncyte Biosciences Distribution B.V.
- FinlandZYNYZIncyte Biosciences Distribution B.V.
- BelgiumZynyz 500 mgIncyte Biosciences Distribution
- IcelandZynyzIncyte Biosciences Distribution B.V.
- NetherlandsZYNYZ 500 mg concentraat voor oplossing voor infusieIncyte Biosciences Distribution B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zynyz
- Liechtenstein · Zynyz
- Norway · Zynyz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/77022676-f8fb-4a0c-94c3-6727c7505a5e GET /v1/drugs/77022676-f8fb-4a0c-94c3-6727c7505a5e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５００ｍｇ２０ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291483A1028",
"category": "注射薬",
"price_yen": 2540,
"generic_name": "レチファンリマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": "2540"
}See everything about レチファンリマブ（遺伝子組換え）.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.